A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Inclusion Criteria: * Patients who have been diagnosed with NMIBC in the previous 2 years, and are attending the urology clinic for standard of care/routine monitoring cystoscopy * Patients 22 years of age or older * Patients who, in the opinion of the Investigator, are suitable for standard urological investigations as part of normal clinical practice * Patients who are, in the opinion of the Investigator, able to understand the purpose of the study and provide a full void urine specimen * Patients who are able to give voluntary, written informed consent to participate in this study Exclusion Criteria: * Patients with known active (symptomatic) calculi within the urino-genitary system * Patients who provide less than 10mL of full void urine * Patients undergoing active treatment for interstitial cystitis * Patients currently undergoing systemic chemotherapy or systemic immunotherapy or radiotherapy. Intravesical chemotherapy or immunotherapy (BCG) is allowed * Patients who have previously been diagnosed with renal cancer, prostate cancer, Muscle Invasive Bladder cancer, an upper tract tumour, or CiS in the prostatic urethra * Patients who have had urological instrumentation to the urinary tract within 14 days prior to the test * Male patients undergoing active treatment for prostatitis